Chatelut Etienne
Université de Toulouse, institut Claudius-Regaud, France.
Bull Cancer. 2011 Nov;98(11):1347-54. doi: 10.1684/bdc.2011.1465.
The interindividual variability in pharmacokinetics represents one of the factors involved in difference of both efficacy and toxicity of anticancer drugs prescribed to patients with the same cancer disease. The causes of pharmacokinetic interindividual variability are themselves divers. The impaired organic function corresponding either to liver or kidneys represents the major cause since any impaired function is systematically responsible of pharmacokinetic modifications, and due to the amplitude of these modifications. In this article, the clinically relevant pharmacokinetic parameters are shown. The methodologies used to study the pharmacokinetic variability due to impaired organic functions and to control them are detailed.
药代动力学的个体间差异是导致患有相同癌症疾病的患者使用抗癌药物时疗效和毒性不同的因素之一。药代动力学个体间差异的原因本身多种多样。肝脏或肾脏对应的器官功能受损是主要原因,因为任何功能受损都会系统性地导致药代动力学改变,且由于这些改变的幅度较大。本文展示了临床相关的药代动力学参数。详细介绍了用于研究因器官功能受损导致的药代动力学变异性并对其进行控制的方法。